KRAS and familial pancreatic carcinoma: RAS mutations are the most frequent proto-oncogene mutations, in which KRAS mutation has the highest incidence in solid tumors (about 86% of the three RAS mutations), i.e., approximately 90% in pancreatic cancer and 40% in colorectal cancer (49, 50).